Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelipepimut S - SELLAS Life Sciences Group

Drug Profile

Nelipepimut S - SELLAS Life Sciences Group

Alternative Names: Cancer vaccine E75; Cancer vaccine E75 - Apthera; Cancer vaccine Her2/neu E75 - Apthera; E75; E75 peptide; E75/GM-CSF vaccine; NeuVax; NPS

Latest Information Update: 11 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer Galena Biopharma; Sellas Life Sciences Group; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Breast cancer
  • No development reported Bladder cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 31 Dec 2021 Galena Biopharma completes a phase II trial for Breast cancer in USA (NCT02297698)
  • 31 Mar 2021 Sellas Life Sciences has patent pending for method of inducing protective or therapeutic immunity against breast cancer with low/intermediate HER2/neu expression in USA, China, European Union, Hong Kong, Japan, South Korea
  • 31 Mar 2021 Sellas Life Sciences has patent pending for modified NPS peptides and methods of their use in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top